Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

MIAMI, FL — The FGC2.3: Feline Vocalization Classification and Cat Translation Project, authored by Dr. Vladislav Reznikov, has crossed a critical scientific milestone — surpassing 14,000 reads on ResearchGate and rapidly climbing toward record-setting levels in the field of animal communication and artificial intelligence. This pioneering work aims to develop the world’s first scientifically grounded…

Tariff-Free Relocation to the US

Tariff-Free Relocation to the US

EU, China, and more are now in the crosshairs. How’s next? It’s time to act. The Trump administration has announced sweeping tariff hikes, as high as 50%, on imports from the European Union, China, and other major markets. Affected industries? Pharmaceuticals, Biotech, Medical Devices, IVD, and Food Supplements — core sectors now facing crippling costs,…

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

This study presents the GDP Matrix by Dr. Vlad Reznikov, a bubble chart designed to clarify the complex relationships between GDP, PPP, and population data by categorizing countries into four quadrants—ROCKSTARS, HONEYBEES, MAVERICKS, and UNDERDOGS depending on National Regulatory Authorities (NRAs) Maturity Level (ML) of the regulatory affairs requirements for healthcare products. Find more details…

Revised ACIP Suggests Postponing MMRV Combination Vaccine, Anticipates Adjustments to Hepatitis B and COVID Vaccination Guidelines

Revised ACIP Suggests Postponing MMRV Combination Vaccine, Anticipates Adjustments to Hepatitis B and COVID Vaccination Guidelines

BMO Capital Markets analysts said the first day of the CDC vaccine advisory committee meeting Thursday had anti-vaccine overtones as the panel, which was revamped by Health Secretary Robert F. Kennedy, Jr. in June, voted to recommend that children under four receive the measles, mumps, rubella (MMR) vaccine separately from a chickenpox vaccine. Today the advisors will vote on changing the childhood schedule for the hepatitis B and COVID-19 vaccines.

Key Takeaways from the CHMP Meeting on Medicinal Products for Humans Held from September 15-18, 2025

14 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its September 2025 meeting.The committee recommended…, CHMP statistics , CHMP statistics: Text versionSeptember 2025 statistics – monthly and cumulative figures for CHMP opinions and withdrawn applications:14 positive opinions on new medicines: 4…, Positive recommendations on new medicines , Enflonsia International non-proprietary name (INN) clesrovimab Marketing…, Imaavy INN nipocalimab Marketing authorisation applicant…, Kyinsu INN insulin icodec / semaglutide  Marketing authorisation applicant…, Lynkuet INN elinzanetant Marketing authorisation applicant…, Positive recommendations on new biosimilar medicines , Acvybra INN Denosumab Marketing authorisation applicant…, Degevma INN denosumab Marketing authorisation applicant…, Denosumab Intas INN denosumab Marketing authorisation applicant…, Gobivaz INN golimumab  Marketing authorisation applicant…, Kefdensis INN denosumab Marketing authorisation applicant…, Ponlimsi INN denosumab Marketing authorisation applicant…, Usgena INN ustekinumab Marketing authorisation applicant…, Xbonzy INN denosumab Marketing authorisation applicant…, Zvogra INN denosumab Marketing authorisation applicant…, Positive recommendations on new generic medicines , Rivaroxaban Koanaa INN rivaroxaban Marketing authorisation applicant…, Positive recommendations on extensions of therapeutic indications , Bimervax INN COVID-19 vaccine  Marketing authorisation holder…, Dupixent INN dupilumab Marketing authorisation holder…, Keytruda INN pembrolizumab Marketing authorisation holder…, Koselugo INN selumetinib Marketing authorisation holder…, Tezspire INN tezepelumab Market authorisation holder…, Uplizna INN inebilizumab Marketing authorisation holder…, Withdrawal of initial marketing authorisation application , Fanskya INN mozafancogene autotemcel Market authorisation applicant…, Amtagvi INN lifileucel Market authorisation applicant…, Tuzodi INN Midazolam Marketing authorisation applicant…, Omforro INN Midazolam Marketing authorisation applicant…, Re-examinations of initial applications , Atropine sulfate FGK INN atropine Marketing authorisation applicant…, Winlevi INN clascoterone Marketing authorisation applicant…, Other updates , Questions and answer on the outcome of assessment on use of Lutathera in treatment of gastro-entero-pancreatic neuroendocrine tumours in adolescentsReference Number: EMA/299422/…, Lunsumio INN mosunetuzumab Marketing authorisation holder…, Norvir INN ritonavir Market authorisation holder…

Brightseed Unveils BioMetaControl to Enhance Metabolic Health and Regulate Blood Sugar Levels

Brightseed Unveils BioMetaControl to Enhance Metabolic Health and Regulate Blood Sugar Levels

Brightseed has launched BioMetaControl, an ingredient composed of n-trans-Caffeoyl Tyramine and n-trans-Feruloyl Tyramine, which the company describes as potent HNF4-alpha agonists identified by its AI platform, Forager, as crucial for blood glucose regulation. A clinical study involving 126 prediabetic participants revealed that BioMetaControl significantly improved fasting blood glucose, fasting insulin and post-meal glucose levels within 30 days at a dose of 120 mg daily. While the study did not achieve normoglycemia, it demonstrated clinically relevant changes, and the results are pending publication in a peer-reviewed journal. BioMetaControl, with its sustained-release formula, marks Brightseed’s expansion into metabolic health.

Exploring the Similarities Between AI Innovations and Traditional Hammers

Exploring the Similarities Between AI Innovations and Traditional Hammers

In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time discussing some of the points brought up in the Bioprocessing Summit last month. They explore the connections between hammers, AI, The Planet of the Apes and monoliths.

Microscopic Robot Revolutionizes Gut Health Evaluation

Microscopic Robot Revolutionizes Gut Health Evaluation

This article is part of our exclusive IEEE Journal Watch series in partnership with IEEE Xplore.

Medical providers have a wide swath of imaging options to help peer inside a patient’s abdomen and assess a health concernbut sometimes a deeper dive is needed in the form of a biopsy. Recently, researchers in China developed a novel, swallowable capsule that is magnetically guided within the gut to perform liquid biopsies.

In a study published in the September issue of IEEE Transactions on Biomedical Engineering, the researchers put the cleverly designed capsule through a series of tests, including in a real intestinal cavity, demonstrating it could potentially be viable in humans one day.

Currently, gut biopsies are collected through invasive procedures, like an endoscopy or a colonoscopy, in which tubes must be inserted into the patient’s body and anesthesia is required. This has prompted scientists to search for less invasive techniques, including swallowable capsules.

Shuang Song, a professor at the School of Robotics and Advanced Manufacture at the Harbin Institute of Technology Shenzhen, notes that many swallowable capsules developed to date have been limited to internal imaging of the gut. Their team wanted to create a minirobot capable of actually sampling liquid in the gut—which, although not as common as a tissue sample, can still yield important insights into gut health. Taking these samples yields more biochemical information, such as gut microbiota composition, metabolites, inflammatory markers, and digestive enzyme activity.

“By collecting intestinal fluid samples, this robot may provide critical information for gut microbiota-related diseases, malabsorption disorders, gastrointestinal bleeding, and early cancer screening,” Song explains. He adds that this approach, compared to traditional tissue biopsies, avoids the risk of tissue damage or bleeding, and is particularly suitable for hard-to-reach areas like the small intestine.

How the Capsule Robot Works

The robot design is simultaneously simple and effective. After the patient swallows the capsule, an external magnetic-sensor-array system tracks the robot’s position and orientation in real time to determine whether it has reached the target sampling area. Once the target area is reached, an external magnetic field is applied to orient the sampling port of the capsule robot toward the intestinal fluid. The magnetic field is then increased to trigger a magnetic spring mechanism inside the capsule.

Two diagrams (top row and bottom row) depict an applied magnetic field rotating the capsule and releasing the chamber. Text in the top row reads "Turn the direction of applied magnetic field." Text in the bottom row reads "Increase the applied magnetic field." By changing the orientation and strength of the applied magnetic field, researchers can direct the capsules and trigger the mechanism that draws in a liquid sample. Shuo Zhang, Shaohui Song, et al.

“This mechanism would then expand the internally compressed flexible membrane chamber, creating negative pressure within the chamber that draws liquid into the capsule robot,” Song explains.

In a way, it’s like reopening a plastic water bottle after a flight, where the changes in pressure cause air to be sucked into the water bottle, reinflating it. In the case of this robotic capsule, the pressure changes cause liquid samples in the gut to be sucked into the capsule.

After the capsule collects its sample and passes through the gut, its outer shell can be removed and the sample analyzed.

The researchers tested a prototype of the robot, which measures 16.3 by 24.4 millimeters, through a series of experiments. In an isolated pig intestine, they show that the capsule can be effectively guided to desired locations using the magnetic field. They also demonstrate that the capsule is able to suck in liquids of different viscositiesincluding the range of viscosity common in the human gutand effectively seal the liquid inside.

“The proposed capsule robot has the advantages of small size and large sampling capacity,” Song says, adding that no internal power supply is needed. “However, our capsule robot is only applicable to liquid sampling and has certain limitations when dealing with solid and solid-liquid mixed samples.”

The team plans to further optimize the size and structure of the capsule robot, improving the shell material to ensure its safety in humans, and test the capsule via experiments in live animals.

Final Results of the Regulatory Affairs Pro Global Survey 2025

Final Results of the Regulatory Affairs Pro Global Survey 2025

Executive Summary Regulatory affairs (RA) professionals in the life sciences industry are navigating a landscape defined by increasingly complex global regulations, rapid technological disruption, and internal organizational pressures. The 2025 study “Challenges and Perspectives for Regulatory Affairs Professionals” reveals pressing concerns around compensation, job security, and competitiveness, alongside emerging debates on artificial intelligence and its…

Showcasing Nature’s Way: A Geothermal Initiative Reflecting Our Dedication to Sustainable Practices

Showcasing Nature’s Way: A Geothermal Initiative Reflecting Our Dedication to Sustainable Practices

Nature’s Way has invested over $12 million in a geothermal project to enhance sustainability by reducing carbon emissions by 20%. The initiative involves drilling 280 wells, each 500 feet deep, to maintain a stable temperature for operating HVAC systems, eliminating the need for five chillers and six boilers. This project aligns with the company’s commitment to supporting nature and sustainability, a value strongly endorsed by its parent company, Schwabe Group. Completion is expected by the third quarter of 2026, reflecting Nature’s Way’s dedication to environmental responsibility and community welfare.